A dysregulated immune response characterized by the hyperproduction of several pro-inflammatory cytokines (a.k.a. ‘cytokine storm’) plays a central role in the pathophysiology of severe coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this Perspective article we discuss the evidence for synergistic anti-inflammatory and immunomodulatory properties exerted by vitamin D and dipeptidyl peptidase-4 (DPP-4) inhibitors, the latter being a class of antihyperglycemic agents used for the treatment of Type 2 diabetes, which have also been reported as immunomodulators. Then, we provide the rationale for investigation of vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i) as an immunomodulation strategy to ratchet down the virulence of SARS-CoV-2, prevent disease progression and modulate the cytokine storm in COVID-19. Lay abstract The so-called ‘cytokine storm’ that drives the hyperproduction of pro-inflammatory mediators, plays a central role in the pathophysiology of severe coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Vitamin D has increasingly been shown to play anti-inflammatory and immunomodulatory properties beyond its role in the regulation of bone homeostasis. Similarly, dipeptidyl peptidase-4 inhibitors (DPP-4i) – a class of antihyperglycemic agents used for the treatment of Type 2 diabetes – have been reported as immunomodulators regardless of their glucose-lowering properties. We, therefore, discuss the role of vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i) as a potential immunomodulation strategy to prevent the development and/or halt the progression of the COVID-19-induced cytokine storm, particularly in patients with diabetes and cardiovascular disease. Tweetable abstract Vitamin D and DPP-4 inhibitors exert anti-inflammatory and immunomodulatory properties. Vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i) may represent a valid therapeutic approach to ratchet down the virulence of SARS-CoV-2 and modulate the cytokine storm in COVID-19.
【저자키워드】 COVID-19, Drug repurposing, SARS-CoV-2, Cytokine storm, Vitamin D, immunomodulation, cardiovascular disease, type 2 diabetes, DPP-4 inhibitors, VIDPP-4i, 【초록키워드】 Treatment, coronavirus, Anti-inflammatory, combination therapy, progression, diabetes, inhibitors, Dipeptidyl peptidase-4, immunomodulator, immunomodulators, pathophysiology, inhibitor, virulence, homeostasis, Evidence, Therapeutic approach, acute respiratory syndrome, Regulation, Abstract, severe coronavirus disease, dysregulated immune response, pro-inflammatory cytokine, immunomodulatory properties, pro-inflammatory mediators, Prevent, synergistic, shown, reported, characterized, modulate, Type, increasingly, diabete, immunomodulatory property, patients with diabete, prevent disease progression, the cytokine storm, 【제목키워드】 combination therapy, inhibitor, modulation,